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QUALITY IMPROVEMENT STUDY

Role of Pharmacogenetics in Improving the Safety of
Psychiatric Care by Predicting the Potential Risks of Mania in
CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder
Santiago Sánchez-Iglesias, MD, PhD, Virginia Garcı́a-Solaesa, BSc, PhD,
Belén Garcı́a-Berrocal, MD, PhD, Almudena Sanchez-Martı́n, PhD,
Carolina Lorenzo-Romo, MD, PhD, Tomás Martı́n-Pinto, MD, Andrea Gaedigk, MS, PhD,
José Manuel González-Buitrago, PhD, and Marı́a Isidoro-Garcı́a, MD, PhD

Abstract: One of the main concerns in psychiatric care is safety
related to drug management. Pharmacogenetics provides an important
tool to assess causes that may have contributed the adverse events
during psychiatric therapy. This study illustrates the potential of pharmacogenetics to identify those patients for which pharmacogeneticguided therapy could be appropriate. It aimed to investigate CYP2D6
genotype in our psychiatric population to assess the value of introducing
pharmacogenetics as a primary improvement for predicting side effects.
A broad series of 224 psychiatric patients comprising psychotic
disorders, depressive disturbances, bipolar disorders, and anxiety disorders was included. The patients were genotyped with the AmpliChip
CYP450 Test to analyzing 33 allelic variants of the CYP2D6 gene.
All bipolar patients with poor metabolizer status showed maniac
switching when CYP2D6 substrates such as selective serotonin reuptake
inhibitors were prescribed. No specific patterns were identified for
adverse events for other disorders.
We propose to utilize pharmacogenetic testing as an intervention to
aid in the identification of patients who are at risk of developing
affective switching in bipolar disorder treated with selective serotonin
reuptake inhibitors, CYP2D6 substrates, and inhibitors.
(Medicine 95(6):e2473)
Abbreviations: BPD = bipolar disorders, BPI = bipolar disorder
type I, CGI = clinical global impression, CPIC = Clinical
Pharmacogenetics Implementation Consortium, EM = extensive
metabolizer, IM = intermediate metabolizer, PM = poor
metabolizer, SSRI = selective serotonin reuptake inhibitor, UM =
ultrarapid metabolizer.

INTRODUCTION

T

he use of pharmacogenetics in psychiatry is increasingly
implemented into clinical practice although there is still
limited information supporting their use.1 Pharmacogenetic
tests are available for the practice of psychiatry to gather genetic
information aimed at personalized medicine.2 Approximately,
25% of currently used drugs are metabolized by CYP2D6.3– 6
To date over 100 allelic variants have been defined for CYP2D6,
(http://www.cypalleles.ki.se/). Updated allele frequencies can
be found in the Clinical Pharmacogenetics implementation
Consortium (CPIC) guidelines.7 Extensive metabolizers
(EMs) are patients with at least 1 fully functional allele.
Ultrarapid metabolizers (UMs) show increased metabolic
activity. The term intermediate metabolizer (IM) refers to
individuals with 1 reduced activity allele and 1 null allele.
Patients with reduced activity may be at greater risk of adverse
events or may bioactivate prodrugs in a less efficient way.4,8
Finally, poor metabolizers (PMs) with 2 nonfunctional alleles
are more likely to experience dose-related adverse drug reactions compared to EM patients.9– 12 Currently, used antidepressant drugs such as paroxetine or fluoxetine are potent inhibitors
of CYP2D6 and their use may alter a patient’s phenotype from
EM to PM in a process called pheno-copying13,14 what constitute an added problem since multiple drugs could have a
potential inhibitory effect on CYP2D6. Our study aimed to
investigate CYP2D6 genotype in our psychiatric population to
assess the value of introducing pharmacogenetics as a primary
improvement for predicting side effects.
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Study Population
A total of 224 patients diagnosed with psychotic disorders,
depressive disturbances, bipolar disorders (BPD), and anxiety
disorders were included. Patients started a medium-term treatment (12–24 months) with antidepressants or antipsychotics
while hospitalized in a short-term unit (54%), and patients on an
outpatient regime (mental health unit) who started pharmacological treatment with antidepressants or antipsychotics for
which a prolonged duration (5 years) of drug therapy was
foreseen (46%) were included. The clinical variables collected
by physicians of the psychiatry service included, among others,
age, gender, ethnicity, diagnosis, medical comorbidities, type
number and duration of psychiatric treatment, clinical global
impression, and adverse drug reaction (UKU scale); physicians
were blinded to genotype results. Regarding ethical issues, the
Institutional Review Board of the University Hospital of Salamanca approved the study; all subjects gave written informed
www.md-journal.com |
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consent to the genetic testing. Aspects related to privacy concerns, protection of participants, and physical well-being
were addressed.

Planing the Intervention
The intervention planned here is based on the pharmacogenetics analysis of our patients by genotyping studies. P450
metabolizer enzymes are considered more likely to influence
drug side effects. The intervention consisted in genotyping
CYP2D6 gene in the psychiatric patients. The AmpliChip
CYP450 Test (Roche Molecular Systems, In Indianapolis)
approved by the Food and Drug Administration in 2005,15
was chosen because analyses 33 allelic variants of CYP2D6
including the most common variants observed across ethnicities. The majority of sequence variations detected are single
nucleotide polymorphisms. The AmpliChip also detects the
presence of a number of CYP2D6 gene duplications and the
CYP2D65 gene deletion. Simultaneously, 2 additional single
nucleotide polymorphisms are interrogated to determine the
presence of CYP2C192 and 3. The analysis was prescribed by
the psychiatrists after collecting the previous information and
performed in the pharmacogenetics laboratory. DNA was
extracted from 1 mL of whole blood collected into EDTAcontaining vacutainers with the MagnaPure Compact system
(Roche Applied Science, Mannheim, Germany). AmpliChip
CPY450 Test was performed as recommended by the manufacturer.16

Methods of Evaluation
The intervention was developed in all patients included in
the study. To assess how well the intervention was implemented
clinical and laboratory supervision was established during all
the study assigning a responsible for each task. It is expected
that the intervention provides information that could be useful
to predict adverse effects in these patients. To assure data
quality, strict control and appropriate scales were used to data
collection. In addition, the genotyping was performed following
the directives of the European Molecular Genetics Management
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Network17 for DNA handling, with the requisite controls. The
application of quality norms followed the UNE-EN-ISO
15189:2007 Normative in the Accredited Section of Molecular
Genetics and Pharmacogenetics of the Clinical Biochemistry
Service of the University Hospital in Salamanca. The normative
included training and qualification of personal, preanalytical,
analytical and postanalytical control, blinding, repeating
measurements, and internal and external validity.

Data Analyses
Qualified statistical analysis was performed with SPSS
v.17 (IBM, Chicago, IL, EEUU). For the analysis of the
qualitative variables the Chi-square test was employed. In order
to compare the qualitative and quantitative variables, ANOVA
was performed after analysis of the homogeneity of variance.
Determination of allele and genotype frequencies was accomplished with the Shesis platform.18

RESULTS
Diagnostic categories observed in our cohort were schizophrenia and other psychotic disorders (F20–29) (n ¼ 76,
33.9%); depressive disturbances (F32–34) (n ¼ 72, 32.1%),
BPD (F30–31) (n ¼ 45, 20.1%), anxiety disorders (F40–43)
(n ¼ 16, 7.1%), and others psychiatric disorders (n ¼ 15, 6.7%).
The mean age of the patients was 45.3 years (SD 15.4) and
56.7% were women. The ethnicity of the subjects was predominantly Caucasian (95.8%).
The intervention provided information about genotype
distribution of CYP2D6 gene and the predicted phenotype.
Of the 224 patients, 4.5% had CYP2D6 genotypes predicting
UM, 9.8% IM, and 6.3% PM metabolizer phenotype. The most
frequently observed genotypes were CYP2D61/2xN for UM
group, 4/41 for IM group, and 4/4 in the PM group. Allele
and genotype frequencies for the study cohort are shown in
Tables 1 and 2. We did not find any correlations between
metabolizer status and the studied disorders. For 6 patients
the AmpliChip CPY450 Test returned ‘‘no-call’’ results that
were solved by other methods.19,20 A total of 90.1% of the

TABLE 1. Allelic Frequencies for CYP2D6 Gene in the Population Studied and in Normal Population19,21,22
CYP2D6 Alleles


1


4


2
41

9

2XN

35

6

5

10

3

17

1XN

41XN

7

29
Total


y

2

Predicted Enzyme Activity

Caucasian Frequency, %19,21,22

Frequency, %y

Number of Allelesy

33–37
12–23
22–33
20
0–3
<2
3–4
<2
2–7
1–2
1–4
<1
<1
<1
<1
0–3
436

38.53
19.72
16.74
7.57
4.59
3.90
2.75
1.61
1.37
0.92
0.46
0.46
0.46
0.46
0.23
0.23

168
86
73
33
20
17
12
7
6
4
2
2
2
2
1
1

Normal
None
Normal
Decreased
Decreased
Increased
Normal
None
None
Decreased
None
Decreased
Increased
Decreased
None
Decreased
100

Frequencies and allele counts for the studied patient population.
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TABLE 2. Distribution of Genotype Frequencies of CYP2D6 Gene in Our Populationy
CYP2D6
Genotype
 

1/ 2
1/ 1
 
1/ 4
 
1/ 41
 
2/ 4
 
4/ 4
 
1/ 2xN
 
4/ 41
 
1/ 35
 
1/ 9
 
4/ 9
 
2/ 2
 
1/ 5
 
2/ 41


2xN/ 4
 
2/ 9


2xN/ 41
 
1/ 10
 
1/ 6
 
9/ 41
 
1/ 17
 
1/ 1xN
 

Predicted
Phenotype

Frequency, %

N (218)

CYP2D6
Genotype

EM
EM
EM
EM
EM
PM
UM
IM
EM
EM
IM
EM
EM
EM
EM
EM
EM
EM
EM
IM
EM
UM

16.51
14.22
12.38
6.42
5.96
5.50
3.21
3.21
2.75
2.75
2.75
2.29
1.83
1.83
1.83
1.38
1.38
0.92
0.92
0.92
0.46
0.46

36
31
27
14
13
12
7
7
6
6
6
5
4
4
4
3
3
2
2
2
1
1

17/ 29

1xN/ 2
 
2/ 10
 
2/ 2xN
 
2/ 3
 
2/ 35
 
2/ 5
 
2/ 6


2xN/ 6


2xN/ 9
 
3/ 35


35/ 35


35/ 41
 
4/ 10
 
4/ 35
 
4/ 41xN
 
4/ 5
 
4/ 6


41/ 41xN
 
6/ 41
 
6/ 9
 
7/ 9







Predicted
Phenotype
IM
UM
EM
UM
EM
EM
EM
EM
EM
EM
EM
EM
EM
IM
EM
IM
PM
PM
IM
IM
IM
IM

Frequency, %
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46
0.46

N (218)
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

EM ¼ extensive metabolizer, IM ¼ intermediate metabolizer, PM ¼ poor metabolizer, UM ¼ ultrarapid metabolizer.
y
The number of patients does not include those with an unknown profile.

patients received at least 1 drug metabolized by CYP2D6. In the
bipolar group 77.8% of patients (35) were diagnosed with
bipolar disorder type I (BPI) and 22.3% (10 patients) were
bipolar disorder type II (BPII). In the total group of BP patients,
3 patients were predicted to be PM (6.7%) and 2 patients to be
IM (4.4%). Interestingly, 4 of these 5 patients (80%) experienced a maniac switching (ie, an episode defined as a sudden
transition from a mood episode to another episode of the
opposite polarity), when a simultaneous substrate and inhibitor
of CYP2D6 was prescribed. There were no associations
between adverse events reported by patients treated for depressive, psychotic or anxiety disorders, and CYP2D6 genotype or
predicted phenotype status. The most relevant outcome of the
intervention was the identification that all bipolar patients with
CYP2D6 PM genotypes experienced these episodes when drugs
that are simultaneous substrate and inhibitors of CYP2D6
were prescribed.

DISCUSSION
Our study aimed to identify the utility of CYP450 genotyping for predicting side effects in psychiatric patients. Clinical
relevance of pharmacogenetic testing is supported by the high
proportion of patients with genotypes predicting either intermediate or PM status of the CYP2D6 enzyme system that
constitutes the main metabolic pathway for a large number
of the psychiatric drugs in current use.
Furthermore, about 80% of patients with EM-predicting
genotypes received drugs that inhibit CYP2D6. These patients
will likely have reduced CYP2D6 capacity or even convert to
the PM phenotype.23 The shift from EM (or IM) to PM status
often appears after treatment with selective serotonin reuptake
Copyright

#

2016 Wolters Kluwer Health, Inc. All rights reserved.

inhibitors (SSRIs), which needs to be considered in clinical
practice. This is especially important when SSRIs are used in
combination with other drugs that are metabolized via the
CYP2D6 pathway.24 Drugs that are simultaneous substrates
and inhibitors of CYP2D6 can contribute to a substantial
reduction in their own metabolism and thereby lead to increase
their plasma levels. It should be noted that more than 200 drugs
could have a potential inhibitory effect on CYP2D6.25
Patients suffering from bipolar disorders may present with
a maniac (or hypomaniac) episode or with depressive episodes.
In the latter case, switching is a major risk during the treatment
of bipolar depression. Our most striking observation was that all
bipolar patients with PM status experienced a maniac episode
after introducing a substrate of CYP2D6 such as paroxetine or
fluoxetine to their treatment regimes. In PM patients, an exaggerated pharmacological response or toxicity would be
expected for drug deactivated by CYP2D6. In this sense,
pharmacokinetic modifications of different psychiatric drugs,
according to the metabolizer status, have been previously
reported. The individualizing drug therapy has been discussed
in the literature26,27 and the CPIC recommends reducing the
dose for SSRIs metabolized by CYP2D6 for PMs.7 A list of our
clinical practice in patients with genetically impaired CYP2D6
metabolism is shown in Table 3.
Several neurobiological factors have been described
associated with mood episode switches28 and the propensity
to mood switches in bipolar patients have been described
subjected to individual differences.29 The treatment emergent
affective switch has been broadly described: antidepressants
have been associated with an increased risk of inducing
mania30,31 and may increase maniac symptom severity32 in
bipolar patients. However, the literature is controversial, that is,
www.md-journal.com |
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TABLE 3. List of Our Clinical Practice in Patients With Genetically Impaired CYP2D6 Metabolism
Considerations
1. Avoid, where possible, drugs with severe general toxicity whose main metabolization pathway is CYP2D6.
2. Avoid, where possible, prodrugs activated by CYP2D6 whose response may be altered.
3. Avoid, where possible, CYP2D6 inhibitor drugs.
4. Control of the use of drugs whose metabolization pathway is CYP2D6; use of slower-release regimens, a closer follow-up and monitor side
effects in a more standardized way. Follow existing guidelines.
5. Use drugs whose metabolization pathway does not depend mainly or exclusively on CYP2D6.

in some clinical trials the number of maniac switches was
similar between placebo and antidepressant groups.33 Pharmacogenetics could help to explain this controversy since the
metabolizer status of the patient likely impacts the response
to drugs used in clinical trials.
We would also like to emphasize that there is uncertainty
regarding the potential harm or benefit associated to antidepressants used in BPD. Recent data suggest absent or very weak
efficacy data for paroxetine in bipolar treatment.34 Although,
European guidelines exert a more allowing attitude, US-guidelines do not recommend antidepressants in bipolar depression,
unless depression is severe. As previously commented, many
factors have been involved in antidepressant induced affective
side-effects, including comorbidities, a history of mania, early
beginning, psychotic features, or even the type of BPD. BPII
subtype has been associated with low switch rates. This is in
accordance to our results because all patients with maniac switch
were BPI. Our aim was to assess CYP2D6 genotype as an
intervention for analyzing the treatment of bipolar patients.
Our findings suggest that a patient’s CYP2D6 metabolic profile
contributes to maniac switching in BPI patients.
Personalizing treatment regimens allow the physician to
avoid certain drug combinations in at-risk patients, that is, those
with reduced or no appreciable CYP2D6 activity. Personalized
medicine research is a more person-centered and thus eventually more humanistic diagnostic and therapeutic approach.35
Pharmacogenetic testing allows specialists to interpret genotyping results within the context of the clinical history providing
guidance for drug selection and dosage. This highlights the
importance for providers to become more aware of the clinical
relevance of pharmacogenomic tests.36 As an example, The
CPIC has published guidelines for CYP2D6 genotypes and
dosing of tricyclic antidepressants2,37,38 and SSRIs.39 A selection of drugs that are commonly used in psychiatry with
pharmacogenomics information in their label per the U.S. Food
and Drug Administration is provided in Table 4. Table 5
provides a list of drugs, whose metabolism does not depend
on CYP2D6 or CYP2D6 is not the main metabolizer.
One of the difficulties in implementing the intervention is
the cost of genotyping; however, the costs of the molecular
methodology are decreasing. In addition, the genotyping is
performed once in life and the information results useful not
only regarding the actual medication but also for all drugs
metabolized by these enzymes. One has to be aware, however,
that genetic variation in other genes, for example, drug transporters or drug targets, as well as other factors likely contribute
to individual drug response.40 We also acknowledge limitations
of this study. For example, the AmpliChip P450 Test does not
capture all known allelic variants for CYP2D6 and other
techniques are needed in these cases. Although the AmpliChip
P450 Test also provides CYP2C19 genotype this test does not

4
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include potentially relevant CYP2C19 alleles such as
CYP2C194 and 17. Therefore, data of this gene are not shown
in this report.

WHAT IS NEW AND CONCLUSIONS
Preemptive genotype-based phenotype (metabolizer status) prediction could be a useful clinical tool for the individualization of the treatment while retrospective genotyping may be
informative regarding adverse events. Subjects at the extreme
distributions of CYP2D6 activity are those at highest risk. Some
commonly used drugs CYP2D6 inhibitors can dramatically
lower a patient’s enzymatic activity and thereby shift the patient
metabolic capacity toward the low end of the activity distribution. In our experience, CYP2D6 genotype information has
been very useful in the psychiatric setting especially in BPD.
Our study provides new insights that are also valuable for future
studies in the field. We demonstrate the utility of pharmacogenetic testing to explain severe adverse events in CYP2D6
PMs diagnosed with BPD. Our observations further support the
implementation of preemptive pharmacogenetic testing as it can
provide substantial benefits increasing drug safety in these
patients. Based on our observations, we propose to consider
pharmacogenetics as a valuable intervention to help identifying

TABLE 4. This Table Provides a Selection of Drugs Commonly
Used in Psychiatric Practice, Which Have Pharmacogenetic
Information in Their Label per the U.S. Food and Drug
Administration
DRUG
Amitriptyline
Atomoxetine
Clomipramine
Clozapine
Desimipramine
Fluoxetine
Fluvoxamine
Iloperidone
Imipramine
Nefazodone
Nortryptyline
Paroxetine
Perphenazine
Pimozide
Protryptiline
Thioridazine
Trimipramine
Venlafaxine

Copyright

#

CYP2D6 Substrate

CYP2D6 Inhibitor

X
X
X
X
X
X
X
X
X

X
X
X
X
X
X
X

X
X
X
X
X
X
X

X
X
X
X
X
X
X
X
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TABLE 5. Metabolism of the Drugs Shown Does Not Depend on the CYP2D6 or CYP2D6 Is Not the Main Pathway
Antidepressants

Antipsychotics

Benzodiazepines

Anticonvulsants

Analgesics

Citalopram
Escitalopram
Mirtazapine
Moclobemida
Sertralina

Asenapine
Olanzapine
Paliperidone

Diazepam
Lorazepam
Lormetazepam
Oxazepam
Temazepam

Fenitoina
Gabapentanoid
Mefenitoina
Phenobarbital
Primidona
Valproic acid

Oxymorphone
Tapentadol

patients at risk to develop affective switching in BPD treated
with SSRIs or other CYP2D6 substrates and inhibitors.

14. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype
assignment from genotype data: a critical assessment and call for
standardization. Curr Drug Metab. 2014;15:218–232.
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